Pulse Biosciences initiates feasibility study to treat patients with cutaneous warts.

|About: Pulse Biosciences (PLSE)|By:, SA News Editor

Pulse Biosciences (NASDAQ:PLSE) initiates a clinical feasibility study using its Nano-Pulse Stimulation (NPS) platform to treat patients with cutaneous warts.

This feasibility study will include up to 20 subjects at the Scripps Clinic in San Diego, CA. Eligible subjects receive NPS treatment(s) followed by evaluations at 7-days, 30-days, and 60-days post-initial NPS treatment.

Patient enrollment, treatment and follow-up are expected to be completed during Q1 2019.

Subscribe for full text news in your inbox